Results suggest that targeting mitochondrial BCKD kinase (BDK) as a pharmacological approach to mitigate the branched-chain amino acids (BCAAs) accumulation in metabolic diseases and heart failure.
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.